The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253)

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 362-368

  Fujishiro, Yuka ^a   Tonogi, Morio ^a   Ochiai, Hiromi ^a   Matsuzaka, Kenichi ^a   Yamane, Gen Yuki ^a   Azuma, Toshifumi ^a  

^a TOKYO DENTAL COLLEGE   (Japan)

Author keywords

Cancer stem cells; Epidermal growth factor receptor; PI3K; Side population cell; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LAPATINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB;

ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CELL ISOLATION; CELL POPULATION; CELL SELECTION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN TISSUE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SALIVARY GLAND TUMOR; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASTIC STEM CELLS; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SALIVARY GLAND NEOPLASMS; SIDE-POPULATION CELLS;

EID: 84862858709     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1434     Document Type: Article

References (32)

1. Wang J, Guo LP, Chen LZ, Zeng YX and Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67: 3716-3724, 2007. (Pubitemid 46762157)
2. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M and Stassi G: Isolation and culture of colon cancer stem cells. Methods Cell Biol 86: 311-324, 2008.
3. Huang D, Gao Q, Guo L, et al: Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 18: 465-473, 2009.
4. Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556, 2007. (Pubitemid 46890873)
5. Shen G, Shen F, Shi Z, et al: Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev Biol Anim 44: 280-289, 2008.
6. Massard C, Deutsch E and Soria JC: Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 17: 1620-1624, 2006. (Pubitemid 44680880)
7. Boman BM and Wicha MS: Cancer stem cells: a step toward the cure. J Clin Oncol 26: 2795-2799, 2008.
8. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E and Johnston P: Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11: 7480-7489, 2005. (Pubitemid 41507709)
9. Ding XW, Wu JH and Jiang CP: ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86: 631-698, 2010.
10. Braun AH, Stark K, Dirsch O, Hilger RA, Seeber S and Vanhoefer U: The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs 16: 1099-1108, 2005. (Pubitemid 41565775)
11. Konecny GE, Venkatesan N, Yang G, et al: Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 98: 1076-1084, 2008. (Pubitemid 351399811)
12. Shipitsin M, Campbell LL, Argani P, et al: Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273, 2007. (Pubitemid 46349843)
13. Hartmann JT, Haap M, Kopp HG and Lipp HP: Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 10: 470-481, 2009.
14. Cristofanilli M: Novel targeted therapies in inflammatory breast cancer. Cancer 116 (S11): 2837-2839, 2010.
15. Chen JS, Pardo FS, Wang-Rodriguez J, et al: EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope 116: 401-406, 2006. (Pubitemid 44318100)
16. Choi S, Sano D, Cheung M, et al: Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 14: 5081-5089, 2008.
17. Alferez D, Wilkinson RW, Watkins J, et al: Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. Mol Cancer Ther 7: 590-598, 2008. (Pubitemid 351482142)
18. Arao T, Yanagihara K, Takigahira M, Takeda M, Koizumi F, Shiratori Y and Nishio K: ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 118: 483-489, 2006. (Pubitemid 41782165)
19. Yajima T, Ochiai H, Uchiyama T, Takano N, Shibahara T and Azuma T: Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int J Oncol 35: 273-280, 2009.
20. Nishimura T, Azuma T, Yokoyama A, Ochiai H, Saito H and Hibi T: New mechanism of transforming growth factor-beta signaling in hepatoma: Dramatic up-regulation of tumor initiating cells and epidermal growth factor receptor expression. Hepatol Res 39: 501-509, 2009.
21. Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006. (Pubitemid 43199589)
22. Takahashi H and Shibuya M: The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109: 227-241, 2005. (Pubitemid 41337127)
23. Nelson MH and Dolder CR: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40: 261-269, 2006. (Pubitemid 43269856)
24. Ryan AJ and Wedge SR: ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92 (Suppl 1): S6-S13, 2005. (Pubitemid 40897411)
25. Siegel-Lakhai WS, Beijnen JH and Schellens JH: Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10: 579-589, 2005. (Pubitemid 41429121)
26. Kitazaki T, Oka M, Nakamura Y, et al: Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49: 337-343, 2005. (Pubitemid 41139146)
27. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J and Yang PC: Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65: 6943-6949, 2005. (Pubitemid 41060734)
28. Dai CL, Tiwari AK, Wu CP, et al: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68: 7905-7914, 2008.
29. Mi Y and Lou L: ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer 97: 934-940, 2007. (Pubitemid 47519322)
30. Tsuchida R, Das B, Yeger H, et al: Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 27: 3923-3934, 2008. (Pubitemid 351913641)
31. Zhou J, Wulfkuhle J, Zhang H, et al: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104: 16158-16163, 2007. (Pubitemid 350099378)
32. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235, 2009.